Michael Schmitz
Stock Analyst at Guggenheim
(2.89)
# 1,777
Out of 5,106 analysts
11
Total ratings
87.5%
Success rate
19.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Maintains: Buy | $3 → $5 | $3.60 | +38.89% | 1 | Nov 14, 2025 | |
| MRSN Mersana Therapeutics | Downgrades: Neutral | n/a | $28.35 | - | 1 | Nov 14, 2025 | |
| MRUS Merus | Downgrades: Neutral | $109 → $97 | $96.93 | +0.07% | 3 | Sep 30, 2025 | |
| GMAB Genmab | Upgrades: Buy | $43 | $31.31 | +37.34% | 1 | Sep 24, 2025 | |
| EXEL Exelixis | Reiterates: Buy | $45 | $40.88 | +10.08% | 1 | Jul 29, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $72 → $82 | $78.92 | +3.90% | 2 | Oct 28, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $12.58 | +217.97% | 1 | Nov 20, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $1.15 | - | 1 | Jan 3, 2023 |
Erasca
Nov 14, 2025
Maintains: Buy
Price Target: $3 → $5
Current: $3.60
Upside: +38.89%
Mersana Therapeutics
Nov 14, 2025
Downgrades: Neutral
Price Target: n/a
Current: $28.35
Upside: -
Merus
Sep 30, 2025
Downgrades: Neutral
Price Target: $109 → $97
Current: $96.93
Upside: +0.07%
Genmab
Sep 24, 2025
Upgrades: Buy
Price Target: $43
Current: $31.31
Upside: +37.34%
Exelixis
Jul 29, 2025
Reiterates: Buy
Price Target: $45
Current: $40.88
Upside: +10.08%
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72 → $82
Current: $78.92
Upside: +3.90%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $12.58
Upside: +217.97%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.15
Upside: -